bpc-157 safety side effects regulatory status and Healing Peptides: Hype or Hope? A Doctor's Comprehensive Perspective – MSK Doctor Zaid Matti Multifunctionality and Possible Medical Application

A Phase 2 trial (NCT01311518) was designed to test RGN-352 in ~75 heart attack patients, but was placed on FDA clinical hold in 2011 due to manufacturing (GMP) compliance issues at the contract site not safety concerns with the drug itself

Last page review: 2026-04-01

By month 4 to 6, patients with tendon and ligament indications have typically moved from pain reduction and mobility improvement to actual strength restoration in the injured structure

For opened multi-dose vials without a different manufacturer date, CDC summarizes USP guidance as 28 days after first puncture. What refrigeration is required for reconstituted peptides